nVerses Capital’s Cytokinetics CYTK Stock Holding History

nVerses Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,500	Closed	-$190K	–	1081
2024 Q2	$190K	Buy	+3,500	New	+$211K	0.11%	283

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

nVerses Capital's CYTK Position: Q3 2024 in Review

nVerses Capital sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 3,500 shares — an estimated $190K sold.

nVerses Capital first reported a position in CYTK in Q2 2024 and held it in 1 quarter. The position peaked at $190K in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

nVerses Capital reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 3,500 Cytokinetics shares in Q3 2024, an estimated $190K.
nVerses Capital first reported a position in Cytokinetics in Q2 2024 and held it in 1 quarter.
nVerses Capital's Cytokinetics position peaked at $190K in Q2 2024.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.